Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies

Alok A. Khorana¹ Jeffrey I. Weitz²

¹Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Avenue, CA60, Cleveland, Ohio, United States
²Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada


Abstract
Venous thromboembolism (VTE) presents a continuing clinical burden to healthcare systems and there are patient groups for whom VTE management is challenging. Depending on the patient profile, the optimal duration of anticoagulation for VTE treatment can be unclear. EINSTEIN CHOICE was a Phase III, randomized, double-blind trial that compared the safety and efficacy of two once-daily (od) doses of the direct, oral factor Xa inhibitor rivaroxaban (20 and 10 mg) with acetylsalicylic acid (ASA; 100 mg daily) for prevention of recurrent VTE. Extended therapy with rivaroxaban at either dose was more effective than ASA at preventing recurrent VTE without increasing bleeding risk. Another group that is challenging to treat in the context of VTE is patients with cancer-associated thrombosis. Cancer is associated with a hypercoagulable state, while cancer treatment itself may increase VTE risk. Evidence supporting the use of non-vitamin K antagonist oral anticoagulants in patients with cancer is growing through specifically designed studies. Cancer Associated thrombosis—exploring solutions for patients through treatment and prevention with ravaroXaban (CALLISTO) is an international research program exploring the role of rivaroxaban for the prevention and treatment of cancer-associated thrombosis. Here, we present overviews of three CALLISTO studies: PRO-LAPS II, CASTA-DIVA and COSIMO. Currently available and anticipated results from studies in a variety of patients at risk of or with VTE will provide valuable insights and seek to optimize future VTE management.

Keywords
► anticoagulation
► extended treatment
► cancer-associated thrombosis
► venous thromboembolism
► rivaroxaban

Introduction
Venous thromboembolism (VTE) is a major cause of morbidity and mortality worldwide. In Europe, it is estimated that VTE is responsible for 544,000 deaths each year.¹ Estimates from the United States suggest that 350,000 to 600,000 patients suffer from VTE each year and up to 100,000 die from their disease.² For hospitalized patients, VTE is the second most common medical complication, the second most common cause of prolonged hospital stay and the third most common cause of in-hospital death.³ VTE predominantly affects older patients; therefore, the global burden of VTE is expected to increase due to an aging population.⁴,⁵ Anticoagulants are the cornerstone of VTE treatment and the American College of Chest Physicians (ACCP) gives preference to the non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) such as warfarin for such therapy.⁶ Treatment is given for at least 3 months at which point the decision to extend therapy is made based on the balance between the risk of recurrent VTE if anticoagulation is
stopped and the risk of bleeding if anticoagulation is continued. Patient preference also factors into the decision. Fear of bleeding often leads to reluctance to extend anticoagulant therapy beyond 3 to 6 months, and a major challenge is identifying patients who would benefit most from extended treatment.  

A second knowledge gap is how to best manage VTE in patients with cancer. Up to 20% of patients with VTE have underlying cancer, and cancer-associated thrombosis (CAT) is the second leading cause of death in such patients. In addition, the diagnosis of VTE in cancer patients may delay cancer treatments, prolong hospital stay and increase healthcare costs. Current guidelines give preference to low-molecular-weight heparin (LMWH) over VKAs or NOACs for the treatment of CAT based on limited data from randomized trials comparing NOACs with VKAs in such patients and the absence of trials comparing NOACs with LMWH for CAT treatment.  

In this review, we identify the areas of unmet clinical needs in these areas and highlight the various trials and initiatives that have investigated, or are currently investigating, rivaroxaban for the extended treatment of VTE (EINSTEIN CHOICE) and the management of CAT (Cancer Associated thrombosis—exploring solutions for patients through treatment and prevention with rivaroxaban [CALLISTO]).

**Prevention of Recurrent VTE: An Unmet Need**

VTE includes deep-vein thrombosis (DVT) and pulmonary embolism (PE). The risk of recurrent VTE can increase over time if anticoagulation therapy is stopped. Indeed, rates of recurrence at 1, 5 and 10 years after stopping anticoagulation following a first episode of clinically symptomatic proximal DVT and/or PE are in the order of 10, 30 and 40%, respectively. In particular, the risk of recurrent VTE reaches more than twofold in patients with unprovoked VTE. Furthermore, the mortality rate in those who experience recurrent VTE events is more than 10%. Although extended anticoagulation therapy reduces the risk of recurrence by at least 80%, there is still controversy regarding which patients should receive such treatment.  

Rivaroxaban, which inhibits factor Xa, is licensed for the initial, long-term and extended treatment of VTE, based on the results of the Phase III EINSTEIN clinical trial program. Compared with conventional treatment consisting of enoxaparin overlapped with a VKA, the EINSTEIN DVT and PE trials showed that rivaroxaban (starting at a dose of 15 mg twice daily [bid] for 21 days followed by 20 mg once daily [od] thereafter) was as effective for prevention of recurrent VTE and was associated with a 50% decrease in major bleeding. Furthermore, rivaroxaban is easier to administer than enoxaparin followed by a VKA because it can be given orally in fixed doses without routine coagulation monitoring.  

EINSTEIN EXT compared the efficacy and safety of rivaroxaban (20 mg od) and placebo for the prevention of recurrent VTE in patients who had already completed 6 to 12 months of anticoagulant therapy for their index event and for whom there was equipoise about the need for continued treatment. Extended treatment with rivaroxaban or placebo was given for 6 or 12 months. Compared with placebo, rivaroxaban was superior and produced an 82% reduction in the rate of recurrent symptomatic VTE (hazard ratio [HR]: 0.18; 95% confidence interval [CI]: 0.09–0.39; p < 0.001) and was associated with a low rate of major bleeding that was not significantly higher than that observed with placebo (0.7 and 0%, respectively; p = 0.11).

Clinical guidelines from the ACCP endorse treatment with NOACs (including rivaroxaban, apixaban, edoxaban and dabigatran) in preference to VKAs for the initial and long-term (first 3 months) treatment of VTE in patients without cancer. However, these guidelines only suggest (rather than recommend) extending therapy beyond 3 months in patients with a first unprovoked VTE and low to moderate bleeding risk. Three months is recommended as the duration of anticoagulation for all other VTE patients without cancer.  

Acetylsalicylic acid (ASA) was compared with placebo for secondary prevention of unprovoked VTE in the Warfarin and Aspirin (WARFASA) and Aspirin to Prevent Recurrent Venous Thromboembolism (ASPIRE) trials. Patients enrolled in these trials had completed 6 weeks to 24 months (ASPIRE) or 6 to 18 months (WARFASA) of anticoagulation therapy for their index VTE event. A combined analysis of the results of these two trials showed that ASA significantly reduced the incidence of recurrent VTE compared with placebo by 32% (HR: 0.68; 95% CI: 0.51–0.90; p = 0.007), without significantly increasing the rate of major bleeding. The current ACCP guidelines suggest the use of ASA in patients with unprovoked proximal DVT or PE who elect to stop anticoagulant therapy, and do not have a contraindication to ASA.  

EINSTEIN CHOICE was designed to determine whether an alternative lower rivaroxaban dose (10 mg od) would provide a similar balance of efficacy and safety as rivaroxaban 20 mg od in offering extended protection from recurrent VTE compared with ASA.  

**EINSTEIN CHOICE: Rivaroxaban for the Extended Treatment of VTE**

EINSTEIN CHOICE was a Phase III, randomized, double-blind trial that compared the safety and efficacy of two different doses of once-daily rivaroxaban (20 and 10 mg) with ASA (100 mg daily) for the prevention of recurrent VTE. The 20-mg od dose of rivaroxaban was chosen because it was shown to be superior to placebo for the prevention of recurrent VTE in the EINSTEIN EXT trial, and the 10-mg od dose of rivaroxaban was chosen because at that dose rivaroxaban was studied as thromboprophylaxis after hip or knee replacement surgery and in medically ill patients. ASA was used as a comparator because compared with placebo, it reduced the risk of recurrent VTE by 32% in previous trials. Patients included in EINSTEIN CHOICE had completed 6 to 12 months of anticoagulation therapy for their index VTE event and had equipoise regarding the need for continued anticoagulation. Study drugs were administered for up to 12 months, with a 1-month follow-up. The primary efficacy outcome was symptomatic recurrent fatal or nonfatal VTE; the principal safety outcome was major bleeding.
A total of 3,365 patients with a median treatment duration of 351 days were included in the intention-to-treat analysis. The primary efficacy outcome occurred in 17 of 1,107 patients (1.5%) receiving rivaroxaban 20 mg od and in 13 of 1,127 patients (1.2%) receiving rivaroxaban 10 mg od, compared with 50 of 1,131 patients (4.4%) receiving ASA (HR for rivaroxaban 20 mg od vs. ASA: 0.34; 95% CI: 0.20–0.59; HR for rivaroxaban 10 mg od vs. ASA: 0.26; 95% CI: 0.14–0.47; p < 0.001 for both comparisons; Fig. 1). The rates of major and clinically relevant non-major (CRNM) bleeding were not significantly different among the three groups (major bleeding HR for rivaroxaban 20 mg od vs. ASA: 2.01; 95% CI: 0.50–8.04, p = 0.32; major bleeding HR for rivaroxaban 10 mg od vs. ASA: 1.64; 95% CI: 0.39–6.84, p = 0.50; CRNM bleeding HR for rivaroxaban 20 mg od vs. ASA: 1.53; 95% CI: 0.87–2.69, p = 0.14; CRNM bleeding HR for rivaroxaban 10 mg od vs. ASA: 1.09; 95% CI: 0.59–2.00, p = 0.78). The incidences of non-critical and fatal bleeding were similar between groups (Fig. 1), as were the incidences of adverse events. Thus, compared with ASA, both doses of rivaroxaban significantly reduced the risk of recurrent VTE by approximately 70% without a significant increase in the rate of major bleeding.

Although the differences in the rates of major plus CRNM bleeding with the 20-mg and 10-mg doses of rivaroxaban were not statistically significant (p = 0.21), there were fewer such bleeding events with the 10-mg dose than with the 20-mg dose (27/1,127 [2.4%] vs. 36/1,107 [3.3%], respectively). In addition, in women who entered into the trial, the intensity and duration of menstrual bleeding events reported with the 10-mg dose were less than those with the 20-mg dose and were similar to the intensity and duration of menstrual bleeding reported with ASA. Therefore, rivaroxaban 10 mg od may have safety advantages over rivaroxaban 20 mg od for extended VTE treatment in patients at risk of bleeding.

EINSTEIN CHOICE included patients with provoked and unprovoked VTE. The recurrence risk in unprovoked VTE is clearly high, while the risk of recurrence remains less clear in those whose VTE was provoked by minor transient or persistent risk factors. So while the results appeared favorable for both groups of patients, clinicians need further clarity on the situations in which extended VTE treatment should be given to those with provoked VTE. In addition, patients who required extended treatment with therapeutic doses of anticoagulant agents were excluded. Therefore, it remains unknown whether rivaroxaban 10 mg od would be sufficient to prevent recurrence in such patients.

Findings from EINSTEIN CHOICE led to label updates by both the European Medicines Agency and the Food and Drug Administration to include extended prevention of recurrent VTE with rivaroxaban 10 mg od following ≥6 months of standard anticoagulation therapy. Rivaroxaban 20 mg od could potentially be continued in patients at high risk for VTE recurrence, for example those whose index VTE event was life-threatening, those with a high risk of thrombophilia, or those who had a recurrence of VTE while receiving other anticoagulants or lower doses of the same anticoagulant. Therefore, with the availability of the two doses of rivaroxaban, the intensity of extended anticoagulation therapy can be individualized based on the relative risks of recurrent VTE and bleeding.

Similar data are available for apixaban. Thus, in the randomized, double-blind Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment (AMPLIFY-EXT) trial, two doses of apixaban (2.5 mg bid and 5 mg bid) were compared with placebo for the prevention of recurrence in patients with VTE who had completed 6 to 12 months of anticoagulation therapy and for whom there was equipoise regarding the need for continued anticoagulation therapy. Study drugs were
administered for 6 months.\textsuperscript{23} Compared with placebo, the prophylactic dose of apixaban (2.5 mg bid) was as effective as the treatment dose (5 mg bid) for prevention of recurrence, and both doses were associated with rates of major and CRNM bleeding similar to those with placebo.\textsuperscript{23} Therefore, in clinical practice, the intensity of VTE treatment with apixaban or rivaroxaban could be tailored in line with the risk of recurrence: a higher dose for initial therapy when the risk of recurrence is greatest (apixaban 10 mg bid for 7 days or rivaroxaban 15 mg bid for 21 days), followed by a treatment dose for 3 to 6 months (apixaban 5 mg bid or rivaroxaban 20 mg od), and then a lower dose for an extended duration to ensure long-term protection (apixaban 2.5 mg bid or rivaroxaban 10 mg od).

Prevention and Treatment of CAT: An Unmet Need

Cancer is associated with a hypercoagulable state resulting from multiple factors, both related to the cancer itself and anticaner therapies.\textsuperscript{24} CAT is a common cause of morbidity and mortality in patients with malignancy.\textsuperscript{7,8,11,25} When treated with conventional therapy consisting of heparin followed by a VKA, patients with CAT are at higher risk of both recurrent VTE and bleeding than VTE patients without cancer.\textsuperscript{26} The treatment of CAT with anticoagulants can be complicated by concurrent systemic therapy, and the need for treatment interruption for invasive diagnostic and other procedures. Individualized anticoagulant treatment duration is based on the clinical status and stage of cancer, the risk of recurrent VTE and bleeding, and patient preference.\textsuperscript{27,28} Risk factors for VTE in cancer patients include the type and stage of cancer, older age, poor performance status, prior history of VTE, presence of a central venous catheter or port, extent of surgery and type of cancer treatment. Hospitalized patients and those receiving chemotherapy are at highest risk of CAT.\textsuperscript{7,11,29,30}

Various guidelines are available for the prevention and treatment of CAT and differ depending on the patient group (Table 1). Guidelines from the ACCP for VTE prevention recommend 4 weeks of thromboprophylaxis with LMWH or fondaparinux after extensive abdominal or pelvic surgery for cancer.\textsuperscript{31} However, in practice, LMWH is usually stopped when patients are discharged.\textsuperscript{32} Routine thromboprophylaxis is not recommended for ambulatory cancer patients except in selected high-risk patients, such as those with multiple myeloma receiving anti-angiogenesis agents with chemotherapy and/or dexamethasone, where prophylaxis with LMWH or low-dose ASA is recommended.\textsuperscript{32–34} The Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology (BCSH) and the European Society for Medical Oncology (ESMO) advise against routine anticoagulant thromboprophylaxis in patients receiving chemotherapy.\textsuperscript{33–35} While the role of primary prophylaxis in some cancer patients is uncertain (i.e. ambulatory patients or those receiving chemotherapy), the availability of scores to identify cancer patients at high risk of VTE (i.e. Khorana score),\textsuperscript{36} as well as the availability of NOACs, renders ongoing trials of thromboprophylaxis feasible. The Khorana score is currently recommended for assessment of risk based on external validation in over 12,000 patients.\textsuperscript{37} Modifications of this score including PROTECHT and Vienna have been proposed but have not been validated.\textsuperscript{37} Ongoing studies of novel biomarker development may improve the performance of this score in risk stratification, but for now this remains the only validated score recommended by guidelines and is currently the basis of several ongoing randomized trials.\textsuperscript{37}

For treatment of VTE in patients with active cancer, the American Society of Clinical Oncology (ASCO), BCSH and ESMO also give preference to LMWH over VKAs and recommend LMWH for at least 6 months.\textsuperscript{32–34} The ACCP guidelines recommend LMWH for initial treatment (the first 3 months),\textsuperscript{6} while recommending extended anticoagulation (no scheduled stop date) for patients without a high bleeding risk and suggesting extended anticoagulation for those with a high bleeding risk.\textsuperscript{5} The preference for LMWH is based on the results of several randomized controlled trials (RCTs) that demonstrated lower rates of recurrence with LMWH than with VKAs in patients with CAT, although the most contemporary of these studies did not meet its primary endpoint.\textsuperscript{38–40} While ASCO does not currently recommend NOACs for VTE treatment in patients with active cancer owing to insufficient evidence, the ACCP guidelines now include NOACs as part of the guidelines for anticoagulation in patients with VTE and cancer within the first 3 months after the VTE event, where LMWH is suggested over VKAs (Grade 2B) and dabigatran, rivaroxaban, apixaban or edoxaban (Grade 2C).\textsuperscript{6,32}

While LMWH is the first choice for the treatment of CAT, the requirement for parenteral administration is a recognized limitation in addition to being resource intensive and inconvenient.\textsuperscript{41} Moreover, the risk of VTE recurrence associated with 6 months of LMWH in cancer patients has been estimated to be 7 to 8% in clinical trials.\textsuperscript{39,40} VKAs have shown lower efficacy than LMWH for the treatment of CAT and limitations include: a narrow therapeutic dosing window; the need for frequent monitoring and dose adjustments; interactions with food and drugs (including chemotherapy); and wide fluctuations in the international normalized ratio in those with hepatic metastases.\textsuperscript{34,35}

The limitations of LMWH and VKAs may result in poor adherence to the anticoagulant therapies recommended in international clinical guidelines. A recent real-world study investigated how frequently the current guidelines are followed by assessing anticoagulation treatment patterns for VTE in newly diagnosed cancer patients in the United States.\textsuperscript{42} Findings showed that VTE occurred in 6.2% of this study population, with a median onset of 181 days after a cancer diagnosis.\textsuperscript{42} Outpatient prescription data showed that warfarin was the most commonly prescribed anticoagulant (50%), followed by LMWH (40%) and other anticoagulants (10%). During a 6-month period, 13% of patients persisted on injectable anticoagulants compared with 30% who persisted on oral anticoagulants—this may be due to the burden of daily self-injection and the high cost of LMWH in the United States.\textsuperscript{42}
Table 1 Guidelines for prevention and treatment of CAT

<table>
<thead>
<tr>
<th>VTE prevention: hospitalized patients with cancer</th>
<th>ASCO\textsuperscript{22}</th>
<th>BCSH\textsuperscript{33}</th>
<th>ESC\textsuperscript{60}</th>
<th>ESMO\textsuperscript{34}</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMWH should be used for VTE undergoing abdominal or pelvic surgery for cancer (Grade 1B)</td>
<td>Hospitalized patients with active malignancy with acute medical illness or reduced mobility: prophylaxis in the absence of bleeding or other contraindications (strong evidence) Thromboprophylaxis may be considered in those without additional risk factors (moderate evidence) Patients undergoing major cancer surgery: prophylaxis with LMWH or UFH starting before surgery and continuing for at least 7–10 d (strong evidence)\textsuperscript{*}</td>
<td>Thromboprophylaxis for patients with active or recent cancer admitted to hospital (2C)</td>
<td>N/A</td>
<td>Hospitalized cancer patients confined to bed with an acute medical complication: thromboprophylaxis with UFH, LMWH or fondaparinux (IA)</td>
</tr>
</tbody>
</table>

| VTE prevention: ambulatory patients with cancer | N/A | Thromboprophylaxis is not routinely recommended for ambulatory patients with cancer; it may be considered for very select high-risk patients (moderate evidence) Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone: prophylaxis with either LMWH or low-dose ASA (moderate evidence) | Recommend against routine thromboprophylaxis in ambulatory cancer patients, unless they are high risk (2B) | N/A |

| Treatment and secondary prevention of CAT | Initial treatment (first 3 mo): suggest LMWH over VKA (Grade 2B), dabigatran (Grade 2C), rivaroxaban (Grade 2C), apixaban (Grade 2C) or edoxaban (Grade 2C) Extended (no scheduled stop date) anticoagulation: recommended in patients who do not have a high bleeding risk (Grade 1B), and suggested for those with a high bleeding risk (Grade 2B) | Initial treatment: LMWH preferred over UFH for the initial 5–10 d\textsuperscript{4} (strong evidence) Long-term: LMWH for >6 mo is preferred over VKAs\textsuperscript{c,d} (strong evidence) Use of NOACs is not currently recommended for patients with malignancy and VTE (insufficient evidence) | Initial treatment should be with LMWH for six mo, if tolerated\textsuperscript{*} (1A) active malignancy: anticoagulation should be continued, taking patient status and wishes and bleeding risk into consideration | Patients with PE and cancer: weight-adjusted LMWH should be considered for the first 3–6 mo (IIa, B) Extended anticoagulation should be considered for an indefinite period or until the cancer is cured (IIa, C) |

| Long-term anticoagulation with LMWH for six mo (IIa) |

\textsuperscript{*}Extending postoperative prophylaxis up to 4 weeks should be considered in those with high-risk features; \textsuperscript{a}Patients with cancer and newly diagnosed VTE who have CrCl >30 ml/min; \textsuperscript{b}VKAs are an acceptable alternative for long-term therapy if LMWH is not available; \textsuperscript{c}Anticoagulation with LMWH or VKA beyond 6 months may be considered for select patients with active cancer, e.g. those with metastatic disease or those receiving chemotherapy (insufficient evidence); \textsuperscript{d}Warfarin and other oral anticoagulants are acceptable alternatives if LMWH is impractical and anticoagulation is indicated (1A). Abbreviations: ACCP, American College of Chest Physicians; ASA, acetylsalicylic acid; ASCO, American Society for Clinical Oncology; BCSH, British Committee for Standards in Haematology; CrCl, creatinine clearance; CAT, cancer-associated thrombosis; d, days; ESC, European Society of Cardiology; ESMO, European Society for Medical Oncology; INR, international normalized ratio; LMWH, low-molecular-weight heparin; mo, months; N/A, not applicable; NOAC, non-vitamin K antagonist oral anticoagulant; PE, pulmonary embolism; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, venous thromboembolism; wk, weeks.
Another recent real-world analysis showed that, despite guideline recommendations, warfarin and rivaroxaban were at least as equally utilized as LMWH for the treatment of CAT; LMWH was associated with significantly lower persistence, shorter duration of treatment and more requirements for switching compared with warfarin or rivaroxaban.43

It is likely that NOACs will present a simple and less costly option than LMWH for the treatment of CAT. Patients with cancer were included in Phase III trials which compared NOACs with VKAs for the treatment of VTE, suggesting that NOACs present a viable alternative to VKAs in this setting.44–48 Despite the fact that these trials were not designed to study patients with cancer specifically, or to compare NOACs with LMWH, the data available so far appear favorable.45,49 and further evidence to support NOAC use in CAT is growing. Studies underway include HOKUSAI-VTE Cancer (edoxaban vs. dalteparin), ADAM-VTE (apixaban vs. dalteparin), CARAVAGGIO (apixaban vs. dalteparin) and CANVAS (rivaroxaban, apixaban, edoxaban or dabigatran vs. LMWH or warfarin).50–53 Investigations into the efficacy and safety of rivaroxaban in CAT are the subject of the ongoing CALLISTO clinical research program.54

The CALLISTO Program: Rivaroxaban for the Prevention and Treatment of VTE in Active Cancer

CALLISTO is an international clinical research program addressing clinical questions in CAT via multiple studies, expert recommendations and clinical registries.54 The overall aim is to explore the potential of rivaroxaban in the prevention and treatment of CAT with a view to improving the quality of care for these patients.54

Studies in the CALLISTO program are summarized in Table 2. They aim to address the following knowledge gaps for rivaroxaban: effectiveness and safety for the prevention and treatment of CAT; patient treatment satisfaction, treatment persistence and quality of life in cancer patients; effectiveness and safety for extended treatment (>6 months) of CAT; treatment dosing in patients with chemotherapy-induced side effects; current strategies for thromboprophylaxis; management of temporary interruptions of rivaroxaban for invasive procedures and provision of continuous anticoagulation for patients with chemotherapy-induced side effects.

Three CALLISTO studies are described in more detail below: PRO-LAPSII, an RCT with rivaroxaban for the prevention of CAT; CASTA-DIVA, an RCT with rivaroxaban for treatment of CAT; and COSIMO, a noninterventional study (NIS) to assess patient-reported treatment satisfaction with rivaroxaban for patients with VTE and active cancer who transition to rivaroxaban therapy.55–57

PRO-LAPS II: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis after Laparoscopic Surgery for Colorectal Cancer

The primary aim of PRO-LAPS II—a Phase III, investigator-initiated, multicentre, randomized, double-blind, placebo-controlled trial—is to assess the efficacy and safety of postdischarge extended (3 weeks) antithrombotic prophylaxis with rivaroxaban 10 mg od vs. placebo after planned laparoscopic surgery for colorectal cancer in patients who had received antithrombotic prophylaxis with LMWH administered for 7 ± 2 days following surgery.55 The primary outcome is a composite of symptomatic objectively confirmed VTE, asymptomatic ultrasonography-confirmed DVT and VTE-related death at 28 ± 2 days after planned laparoscopic surgery.55 Approximately 650 patients are anticipated to be enrolled in PRO-LAPS II.55 – Fig. 2 shows the study design for PRO-LAPS II.

CASTA-DIVA: Efficacy and Safety of Oral Rivaroxaban for the Treatment of VTE in Patients with Active Cancer. A Pilot Study

CASTA-DIVA is a prospective, multicentre, randomized, open-label, noninferiority pilot trial with blinded adjudication of endpoints.56 The aim of the study is to compare the efficacy and safety of rivaroxaban (15 mg bid for 21 days, then 20 mg od) and dalteparin (200 IU/kg for 4 weeks, then 150 IU/kg) for the treatment of VTE in patients with active cancer at high risk of VTE recurrence, defined by a modified Ottawa score. The primary outcome is recurrent VTE, including all symptomatic or incidental DVT/PE and worsening of pulmonary vascular obstruction or venous obstruction. The secondary outcomes include major bleeding, as defined using the International Society on Thrombosis and Haemostasis (ISTH) criteria, CRNM bleeding, symptomatic recurrent PE or DVT, and pharmacokinetic parameters. Approximately 200 patients with active cancer are anticipated for enrolment in CASTA-DIVA.56 – Fig. 3 shows the study design for CASTA-DIVA.

COSIMO: Cancer-Associated Thrombosis—Patient-Reported Outcomes with Rivaroxaban (a Noninterventional Study on Patients Changing to Rivaroxaban for Treatment of VTE and Prevention of Recurrent VTE in Patients with Active Cancer)

COSIMO is an international, prospective, noninterventional cohort study.57 This study uses the Anti-Clot Treatment Scale (ACTS), a 15-item patient-reported validated instrument that monitors patient satisfaction. The ACTS includes a 12-item ACTS burdens scale and a 3-item ACTS benefits scale.58

The aim of the study is to assess patient-reported treatment satisfaction according to the ACTS burden score for the use of rivaroxaban for the treatment of VTE and/or prevention of recurrent VTE in patients with active cancer switching to rivaroxaban therapy.57 The primary objective of the study is measurement of patient-reported treatment satisfaction based on the ACTS burden score. Other outcomes include treatment satisfaction over time, patient preferences and patient quality of life.57 Approximately 500 patients are anticipated for the enrolment in the COSIMO study. – Fig. 4 shows the study design for COSIMO.
<table>
<thead>
<tr>
<th>Trial</th>
<th>Design</th>
<th>Dose</th>
<th>Duration</th>
<th>Population</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>VTE Prevention</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASSINI</td>
<td>Prospective, randomized, double-blind superiority (~700 patients)</td>
<td>Rivaroxaban 10 mg od vs. placebo</td>
<td>6 mo</td>
<td>Ambulatory cancer patients at high VTE risk planned to initiate chemotherapy</td>
</tr>
<tr>
<td>PRO-LAPS II</td>
<td>Randomized, double-blind (~650 patients)</td>
<td>Rivaroxaban 10 mg od vs. placebo</td>
<td>Extended antithrombotic prophylaxis (3 wk)</td>
<td>Colorectal cancer patients after laparoscopic surgery</td>
</tr>
<tr>
<td><strong>VTE Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SELECT-D</td>
<td>Randomized, open-label, multicentre pilot (~530 patients)</td>
<td>Rivaroxaban vs. dalteparin, rivaroxaban vs. placebo</td>
<td>6 mo</td>
<td>Patients with active cancer and first objectively confirmed VTE</td>
</tr>
<tr>
<td>CASTA-DIVA</td>
<td>Randomized, open-label, noninferiority (~200 patients)</td>
<td>Rivaroxaban vs. dalteparin</td>
<td>3 mo</td>
<td>Patients with active cancer at high risk of VTE recurrence</td>
</tr>
<tr>
<td>CONKO-011</td>
<td>Prospective, randomized, open-label, multicentre (~450 patients)</td>
<td>Rivaroxaban vs. LMWH</td>
<td>3 mo</td>
<td>Patients with active cancer and newly diagnosed acute VTE</td>
</tr>
<tr>
<td>QA</td>
<td>Following up CAT patients whose full anticoagulation course was rivaroxaban for 6 mo (~200 patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COSIMO</td>
<td>Patient-reported outcomes, follow-up of 6 mo (~500 patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontline2</td>
<td>Second CAT survey of up to 5,000 oncologists/haematologists to identify current practice</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Dalteparin (200 IU/kg daily subcutaneously for 1 month and 150 IU/kg for months 2–6); and rivaroxaban (15 mg bid for 21 days and 20 mg od for 6 months in total).

*Dalteparin 200 IU/kg daily for 4 weeks followed by 150 IU/kg daily for 8 weeks or rivaroxaban 15 mg bid for 21 days followed by 20 mg od for 9 weeks.

*Therapeutic licensed dose of LMWH according to standards of the individual study centre or rivaroxaban 15 mg bid for 21 days, followed by 20 mg od over a period of 3 months.

Abbreviations: bid, twice daily; CAT, cancer-associated thrombosis; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; mo, months; od, once daily; PE, pulmonary embolism; RVT, residual vein thrombosis; VTE, venous thromboembolism; wk, weeks.
**PRO-LAPS II**

**Objective:** To assess the efficacy and safety of oral rivaroxaban for the extended prophylaxis of venous thromboembolism after laparoscopic surgery in patients with colorectal cancer.

**Population:** Laparoscopic surgery for colorectal cancer

N=950

Rivaroxaban: 10 mg od

Placebo

Day 0

Day 7±2

Day 38±2

Fig. 2 PRO-LAPS II study design.55 Estimated enrolment. Abbreviations: cCUS, complete compression ultrasound; od, once daily; R, randomized; VTE, venous thromboembolism.

**CASTA-DIVA**

**Objective:** To assess the efficacy and safety of rivaroxaban versus dalteparin for the treatment of VTE in patients with active cancer at high risk of VTE recurrence.

**Population:** Patients with active cancer and symptomatic VTE at high risk of recurrence.

N=200

Rivaroxaban: 15 mg bid for 21 days then 20 mg od

Dalteparin: 200 IU/kg for 4 weeks then 150 IU/kg

3 months

Fig. 3 CASTA-DIVA study design.56 Presence of measurable disease or ongoing/planned chemotherapy, radiotherapy or targeted therapy.

†Assessed using the modified Ottawa score. Abbreviations: Bid, twice daily; od, once daily; VTE, venous thromboembolism.

**COSIMO**

**Objective:** To assess patient-reported treatment satisfaction with regard to the ACTS burden score for the use of rivaroxaban for treatment of VTE and/or prevention of recurrent VTE in patients with active cancer changing to this therapy.

**Population:** Patients with active cancer and PE/DVT and/or recurrent PE/DVT

Decision to change to rivaroxaban: N=500

Rivaroxaban: Observation period: 6 months

ACTS

Baseline

Month 1

Month 3

Month 6

DCE

4–12 weeks after start with rivaroxaban/telephone interview

Fig. 4 COSIMO study design.57 Abbreviations: ACTS, anticlot treatment scale; DCE, discrete choice experiment; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; SOC, standard of care; VKA, vitamin K antagonist; VTE, venous thromboembolism.
Conclusion

Several studies have emerged recently that seek to close knowledge gaps in VTE management: the novel ‘umbrella’ program, CALLISTO, involves multiple parallel clinical initiatives with a variety of study designs addressing hypotheses in patients with CAT, or who are at risk of VTE. Published findings to date from the Quality Assessment Initiative (QAI) conducted in 200 patients with active cancer and symptomatic proximal DVT or PE at Memorial Sloan Kettering showed that rivaroxaban had favorable safety and efficacy when it was incorporated into a clinical pathway that provided guidance for its use in the oncology setting.59 Future CALLISTO data will hopefully reduce the burden and consequences of CAT for patients with malignancy. With regards to extended VTE treatment, the EINSTEIN CHOICE data provide expanded treatment options with two rivaroxaban doses (10 mg or 20 mg od), depending on the patient benefit-risk profile. Findings from such studies may ultimately lead to more comprehensive treatment strategies for optimal VTE management in the short and long term, particularly for those who have had limited options to date.

What is known about this topic?

Venous thromboembolism (VTE) presents a continuing clinical burden to healthcare systems and there are patient groups for whom VTE management is challenging. Depending on patient characteristics, the optimal duration of anticoagulation for VTE treatment can be unclear. Another group that is challenging to treat in the context of VTE is patients with cancer-associated thrombosis (CAT). In the prevention and treatment of CAT, there are limited or no data from randomized trials trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin K antagonists or low molecular weight heparin.

What does this paper add?

In the setting of extended VTE treatment, novel data from the Phase III EINSTEIN CHOICE trial are summarized, which subsequently led to label updates by both the European Medicines Agency and the Food and Drug Administration to include extended prevention of recurrent VTE with rivaroxaban 10 mg once daily following ≥6 months of standard anticoagulation therapy. The ‘umbrella’ program, Cancer Associated thrombosis – exploring solutions for patients through Treatment and prevention with rivaroxaban (CALLISTO), involves multiple parallel clinical initiatives with a variety of study designs addressing hypotheses in patients with CAT, or who are at risk of VTE. Several of the studies are a focus of this article. Future CALLISTO findings may help to reduce the burden and consequences of CAT for patients with malignancy.

Conflicts of Interest

A.K. is a consultant/advisory board member for Janssen, Sanofi, Leo Pharma, Bayer AG, Halozyme, Pfizer, Genentech, AngioDynamics, Boehringer Ingelheim and Daiichi Sankyo. J.W. has served as a consultant and has received honoraria from IONIS Pharmaceuticals, Janssen, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Merck and Daiichi Sankyo.

Acknowledgements

The authors would like to acknowledge Kelly Farrell at Ketchum (Inspired Science), who provided editorial support with funding from Bayer AG.

References

1. Heit J. Poster 68. American Society of Hematology 47th Annual Meeting; Atlanta, GA; December 10–13, 2005


Boonyawat K, Lensing A, Prins M, et al. Menstrual Bleeding Patterns in Women Treated with Rivaroxaban: Data from the EINSTEIN CHOICE Trial. ISTH Academy; 2017


PharmaTimes online. EU OKs low-dose Xarelto to prevent recurrent VTE. Available at: http://www.pharmatimes.com/news/4010s_low-dose_xarelto_to_prevent_recurrent_vte_1210333; Accessed January 31, 2018


van Es N, Coppers M, Schulman S, Middeldorp S, Büllers HR. Direct oral anticoagulants compared with vitamin K antagonists for...

50 ADAM-VTE. ClinicalTrials.gov Identifier: NCT02585713. Available at: https://clinicaltrials.gov/ct2/show/NCT02585713; Accessed January 31, 2018

51 Cancer HOKUSAI-VTE. ClinicalTrials.gov Identifier: NCT02073682. Available at: https://clinicaltrials.gov/ct2/show/NCT02073682; Accessed January 31, 2018

52 CARAVAGGIO. ClinicalTrials.gov Identifier: NCT03045406. Available at: https://clinicaltrials.gov/ct2/show/NCT03045406; Accessed January 31, 2018

53 CANVAS. ClinicalTrials.gov Identifier: NCT02744092. Available at: https://clinicaltrials.gov/ct2/show/NCT02744092; Accessed January 31, 2018


55 PRO-LAPSII. ClinicalTrials.gov Identifier: NCT03055026. Available at: https://clinicaltrials.gov/ct2/show/NCT03055026; Accessed January 31, 2018

56 CASTA-DIVA. ClinicalTrials.gov Identifier: NCT02746185. Available at: https://clinicaltrials.gov/ct2/show/NCT02746185; Accessed January 31, 2018

57 COSIMO. ClinicalTrials.gov Identifier: NCT02742623. Available at: https://clinicaltrials.gov/ct2/show/NCT02742623; Accessed January 31, 2018


61 CASSINI. ClinicalTrials.gov Identifier: NCT02555878. Available at: https://ClinicalTrials.gov/show/NCT02555878; Accessed January 31, 2018

62 Warwick Clinical Trials Unit. SELECT-D. Anticoagulation Therapy in SELECTed Cancer Patients at risk of recurrence of venous thromboembolism. Available at: http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/cancer/select-d/; Accessed January 31, 2018


64 CONKO-011. ClinicalTrials.gov Identifier: NCT02583191. Available at: https://ClinicalTrials.gov/show/NCT02583191; Accessed January 31, 2018

65 Thrombosis Research Institute. Frontline2. Fundamental Research in Oncology and Thrombosis (FRONTLINE 2) Survey. Available at: http://frontline2.tri-london.ac.uk/; Accessed January 31, 2018